A clinical trial to study the levels of vascular endothelial growth factor in the fluid in the front part of the eye in cases of occlusion of venous supply of the eye and to correlate with the clinical features and nerve thickness as obtained by scanning and nerve function tests

Aqueous vascular endothelial growth factor (VEGF) profile in central retinal vein occlusion (CRVO) and its correlation with clinical features, spectral domain optical coherence tomography(SD OCT), electroretinogram (ERG) and macular integrity assessment (MAIA) - ProCRVO

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/12/003270

Enrollment

Registered

2012-12-31

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- central retinal vein occlusion

Interventions

Intervention1: Aqueous Tap, ERG,FFA,MAIA,SDOCT: 0.01 ml of aqueous fluid will be collected from the anterior chamber at presentation,1 month, 3 months and 6 months Control Intervention1: Greater than5

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria • Patients with central retinal vein occlusion who are treatment naÃ¯ve with or without visual loss • Patients with well controlled DM will be included when the other eye has less than severe non proliferative diabetic retinopathy

Exclusion criteria

Exclusion criteria: Exclusion Criteria • Ocular intervention within 3 months like intra ocular surgery, intravitreal steroid/anti VEGF injections and previous history of retinal laser treatment. • Neovascular glaucoma • IOP > 21 mmHg • Ocular inflammatory conditions • Age related macular degeneration

Design outcomes

Primary

Measure	Time frame
â?¢ To study the aqueous levels of VEGF in central retinal vein occlusion â?¢ To correlate the aqueous VEGF levels visual acuity,relative afferent pupillary defect,SD OCT,MAIA and number of anti VEGFs required over 6 monthsTimepoint: 1,3,6 months	—

Secondary

Measure	Time frame
To correlate aqueous VEGF levels with number of capillary non perfusion areas in fundus fluorescein angiography whenever feasible â?¢ To correlate aqueous VEGF with MAIA â?¢ To correlate aqueous VEGF levels with standard full field ERG â?¢ To analyze the proportion of patients converting from non ischemic to ischemic CRVO and its correlation with aqueous VEGF levels Timepoint: 1,3,6 months	—

Countries

India

Contacts

Public ContactIndu Govindaraj

Narayana Nethralaya

aing25@gmail.com08884671444

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026